CA-SIGHTCALL
8.9.2021 10:02:12 CEST | Business Wire | Press release
SightCall, the world’s leading augmented reality (AR)-powered visual assistance platform, today announced its partnership with Italy’s Lavazza Group to offer AR-powered remote visual assistance for customer care and maintenance of its coffee machines. One of the world’s most important coffee roasters and a global enterprise with products and distributors in more than 140 countries, Lavazza Group is accelerating its use of virtual assistance technologies to support the ongoing expansion of its product portfolio and continued efforts to become more responsive to fast-changing consumer needs.
“We are proud to partner with Lavazza Group to provide global service solutions for easier and faster product maintenance and repair,” said Thomas Cottereau, founder and CEO of SightCall. “Now more than ever, the world’s top brands are turning to digital support that allows them to provide issue resolution with minimal service disruption. SightCall will enable Lavazza to work through customer care issues immediately, maintaining their hard-earned reputation for high-quality coffee products.”
SightCall provides the company with a comprehensive visual support tool for customer service agents to guide customers to troubleshoot issues, such as descaling coffee machines or basic accessory maintenance remotely. The AR interface lets remote agents draw, point and highlight onto the customer’s smartphone, and high-definition picture assures the highest call qualities even in low-bandwidth environments. Device-agnostic, SightCall performs on a range of user products from smartphones and tables to specialist equipment such as smart glasses.
Lavazza Group, with more than 4,000 employees and revenues of more than EUR 2 billion (2020 Financial Statement), switched to SightCall from a previous visual assistance provider. This decision stemmed from its desire to move from a local approach to a global template offering maximum portability and seamless CRM integration, reinforced by strong GDPR compliance.
Lavazza first piloted SightCall with its customer service teams in France and Germany in the middle of the COVID-19 lockdown in April. Customer support teams were impressed by the ease of use and the level of confidence quickly developed with the tool, providing them with good insight into how a long-term partnership would work.
The company has plans to scale up usage to 130+ customer support agents in seven countries over the next three years. The company plans to cover multiple regions of the world where it provides products, bolstered by the SightCall app’s ability to operate in 13 different languages. Lavazza will also increase the number of codes and use cases it applies SightCall to, with more readily available data from its CRM and responses to SightCall customer surveys telling it where visual assistance can best be deployed to resolve maintenance issues.
“Everywhere our coffee is consumed, Lavazza innovates to enhance the experiences of our customers and consumers, providing fast and accessible service when and where they need it,” said Maria Cristina Aspesi, Lavazza Group Customer Care Director. “With SightCall, we have chosen a solution that gives both central and local customer care teams a single, cutting-edge tool to help customers and consumers, increasing the number of support and interaction cases that can be solved instantaneously.”
About SightCall
SightCall is the world’s leading augmented-reality powered video cloud platform, delivering live, remote interactions between business and customers on every continent around the globe. In a connected, mobile-first world, businesses leveraging SightCall have the ability to see what their customers see and guide them remotely. With nearly 15 years of experience in remote video assistance, SightCall helps businesses transform their customer service and field service with the power of augmented reality and live video. The company has offices in San Francisco (HQ), Austin, Boston, Frankfurt, London, Melbourne, Paris and Singapore. Visit sightcall.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005412/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom